Israeli Study: One in 3 infants Suffer SSRI Withdrawal
It is astonishing how untrustworthy loosely given advice about the safety of SSRI antidepressants by medical professionals and academic institutions.
It is astonishing how untrustworthy loosely given advice about the safety of SSRI antidepressants by medical professionals and academic institutions.
An independent review by a team of German analysts published in the American Journal of Psychiatry confirms that corporate bias is ubiquitous in clinical trials.
Benedict Carey of The New York Times reports with a degree of healthy skepticism about the latest scientific hoopla: Neuroscientists’ infatuation with brain imaging techniques.
"Soon, intuition and the personal experience of friends and family may seem as trustworthy as advice from a doctor in diagnosing an illness or judging a treatment."
"modern pharmacological treatment may be no more beneficial than older ones, despite their added cost."
A major 17-year follow up study published in the British Journal of Psychiatry [1] found a 2.84 times (95% CI 2.06–3.90) increased risk of mortality in people with schizophrenia compared to those not so diagnosed, and with each addition of a neuroleptic (antipsychotic) drug, the risk increased another 2.50.
"Mr. Stanley says he has donated nearly $300 million — including about $35 million in 2005 — to Dr. Torrey’s efforts, the bulk of it for research at universities and start-up drug companies."
"After another four months or so on antidepressants, bringing me to a total of 10 months between the steroids and antidepressants, I was suddenly flipped into this hypomania."
By denigrading all non-chemical interventions, by focusing narrowly on drugs and drugs alone, psychiatry has signed away its profession status.
"This is a critical moment: if the system of peer-review is not any longer able to guarantee the reliability of scientific research, this means that science has lost its way."
IOM committee members were highly critical of FDA’s advisory panels that regularly “recommend” approval without analyzing the safety data.